• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Multiple facets of ADA2 deficiency: Vasculitis, auto-inflammatory disease and immunodeficiency: A literature review of 135 cases from literature.
Authors: Fayand A, Sarrabay G, Belot A, Hentgen V, Kone-Paut I, Grateau G, Melki I, Georgin-Lavialle S Abstract Deficiency of adenosine deaminase 2 (DADA2) is a recently described auto-inflammatory disorder. It is an autosomal recessive inherited disease, caused by mutations in the ADA2 gene (formerly known as CECR1) encoding ADA2 enzyme. Besides its role in the purine metabolism, it has been postulated that ADA2 may act as a growth factor for endothelial cells and in the differenciation of monocytes. Thus, deficiency of ADA2 would lead to endothelial damage and a skewing of monocytes into M1 pro-inflammatory macro...
Source: Revue de Medecine Interne - December 25, 2017 Category: Internal Medicine Tags: Rev Med Interne Source Type: research

Ntox-08. safety of intra-arterial chemotherapy in the treatment of brain tumours
The treatment of brain tumors is greatly limited the delivery impediment caused by the blood-brain barrier and blood-tumor barrier. To circumvent this limitation, different approaches have been studied, including intra-arterial delivery. Because of a significant local increase in plasma-peak concentration, this strategy increases the local area under the curve, and translates into a 3 to 5.5 fold increase in intra-tumoral chemotherapy concentration. However, intra-arterial chemotherapy in the treatment of brain tumors has a notoriously bad name, thanks to prior trials led in past decades showing significant neurotoxicities...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Fortin, D., Caux, S., Gahide, G. Tags: NEUROTOXICITY OF THERAPY Source Type: research

Methotrexate induced leucoencephalopathy: A stroke mimic
We describe the case of a 17 year old girl with acute lymphoblastic leukemia, who developed stroke like episodes on two consecutive challenges with a chemotherapeutic regime which included intravenous and intrathecal methotrexate. She had MRI changes consistent with acute ischemic stroke on both occasions. Her deficits recovered completely and spontaneously, as did the MRI changes. She did not have any further episodes when methotrexate was excluded from the chemotherapeutic regime.
Source: Annals of Indian Academy of Neurology - August 26, 2013 Category: Neurology Authors: Tushar D GosaviMohammed Tauqeer AhmadLai-Heng LeeShih-Hui Lim Source Type: research